Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches
The proliferation in the last few years of cannabidiol (CBD)-containing products in the U.S. markets has been greatly accelerated by changes in the regulatory environment, and by perceptions of their health benefits and presumed safety. The result has been aggressive marketing of many types of products, some of dubious quality, making or implying drug-type claims. The recent approval by the U.S. Food and Drug Administration (FDA) of CBD in the form of Epidiolex®, further complicates the regulatory picture. In addition, a number of studies suggest that, at least at high doses, there may be serious adverse effects or drug interactions associated with CBD. At present, CBD-containing products do not meet the strict definition of dietary supplements, but the FDA is continuing to consider some framework under which they might be allowed. Meanwhile, FDA has adopted a “risk-based” enforcement policy. Possible approaches to a new framework for regulation of CBD products as dietary supplements are discussed here, including expanded research emphasis, a robust corporate stewardship program, and a rigorous adverse event reporting program.
Keywords: Cannabidiol; dietary supplements; regulations.
Wagoner KG, Lazard AJ, Romero-Sandoval EA, Reboussin BA. Wagoner KG, et al. Cannabis Cannabinoid Res. 2021 Dec;6(6):559-563. doi: 10.1089/can.2020.0166. Epub 2021 Jun 17. Cannabis Cannabinoid Res. 2021. PMID: 34142863 Free PMC article.
Koturbash I, MacKay D. Koturbash I, et al. J Diet Suppl. 2020;17(5):487-492. doi: 10.1080/19390211.2020.1796886. Epub 2020 Jul 25. J Diet Suppl. 2020. PMID: 32715797
Marinotti O, Sarill M. Marinotti O, et al. J Diet Suppl. 2020;17(5):517-526. doi: 10.1080/19390211.2020.1776806. Epub 2020 Jun 16. J Diet Suppl. 2020. PMID: 32543253
Cogan PS. Cogan PS. Expert Rev Clin Pharmacol. 2019 Jun;12(6):501-511. doi: 10.1080/17512433.2019.1612743. Epub 2019 May 7. Expert Rev Clin Pharmacol. 2019. PMID: 31025586 Review.
Britch SC, Babalonis S, Walsh SL. Britch SC, et al. Psychopharmacology (Berl). 2021 Jan;238(1):9-28. doi: 10.1007/s00213-020-05712-8. Epub 2020 Nov 21. Psychopharmacology (Berl). 2021. PMID: 33221931 Free PMC article. Review.
Norton JC, Politis MD, Bimali M, Vyas KS, Bircan E, Nembhard WN, Amick BC, Koturbash I. Norton JC, et al. J Diet Suppl. 2023;20(2):171-198. doi: 10.1080/19390211.2022.2128500. Epub 2022 Sep 30. J Diet Suppl. 2023. PMID: 36178162
Salehi A, Puchalski K, Shokoohinia Y, Zolfaghari B, Asgary S. Salehi A, et al. Front Pharmacol. 2022 Jun 27;13:906038. doi: 10.3389/fphar.2022.906038. eCollection 2022. Front Pharmacol. 2022. PMID: 35833025 Free PMC article. Review.
Reece AS, Hulse GK. Reece AS, et al. Environ Epigenet. 2022 May 17;8(1):dvac012. doi: 10.1093/eep/dvac012. eCollection 2022. Environ Epigenet. 2022. PMID: 35782486 Free PMC article.
Reece AS, Hulse GK. Reece AS, et al. Environ Epigenet. 2022 Mar 1;8(1):dvac006. doi: 10.1093/eep/dvac006. eCollection 2022. Environ Epigenet. 2022. PMID: 35386387 Free PMC article.
Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barré T. Fortin D, et al. Front Psychiatry. 2022 Mar 17;13:829944. doi: 10.3389/fpsyt.2022.829944. eCollection 2022. Front Psychiatry. 2022. PMID: 35370865 Free PMC article.